SCHEMBL6538499

SCHEMBL6538499

CCCCNC(=O)COc1ccc([C]=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.63
RECQL P46063 1/20 0.63
ALDH1A1 P00352 1/20 0.56
MGLL Q99685 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
SIRT3 Q9NTG7 1/20 0.50
KDM4E B2RXH2 2/20 0.49
ACHE P22303 1/20 0.49
KMT2A Q03164 1/20 0.49
RAB9A P51151 2/20 0.49
CYP3A4 P08684 1/20 0.49
HDAC1 Q13547 1/20 0.49
NPC1 O15118 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538868 0.84 RAB9A (0.65) TSHRRECQLALDH1A1CYP1A2CYP2D6
SCHEMBL4860148 0.83 RECQL (0.81) TSHRRECQLALDH1A1CYP1A2SIRT3
SCHEMBL6539069 0.82 TSHR (0.67) TSHRRECQLALDH1A1SIRT3
SCHEMBL6538501 0.81 TSHR (0.61) TSHRRECQLALDH1A1CYP1A2CYP2D6
SCHEMBL7195903 0.79 TSHR (0.63) TSHRRECQLALDH1A1KDM4EKMT2A
SCHEMBL7195953 0.79 TSHR (0.63) TSHRRECQLALDH1A1KDM4EKMT2A
SCHEMBL8366672 0.79 RECQL (0.79) TSHRRECQLCYP1A2KDM4EKMT2A
SCHEMBL6539438 0.78 KMT2A (0.51) RECQLALDH1A1KDM4EKMT2ARAB9A
SCHEMBL6538862 0.78 SMN1; SMN2 (0.71) ALDH1A1RAB9AHDAC1NPC1SMN1; SMN2
SCHEMBL10599988 0.78 RECQL (0.77) TSHRRECQLCYP1A2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB TSHR 689/4885RECQL 2539/4885ALDH1A1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.